Report: Annual VC investment in genomics companies rises 142% since 2016

Jessica Kim Cohen - Print  | 

Genomics companies in the U.S. received $2.52 billion in venture capital funding in 2017, up 142 percent from $1.04 billion in 2016, according to a joint report by PwC and CB Insights.

The majority of the $2.52 billion in funding, roughly $1.7 billion, went toward companies focused on disease diagnosis. The second most-funded genomics sector was biotechnology at $550 million.

Here are the five genomics companies that received the most VC funding during the fourth quarter of 2017.

1. Menlo Park, Calif.-based Grail: $238 million

2. South San Francisco, Calif.-based Counsyl: $80 million

3. Baltimore-based Personal Genome Diagnostics: $65 million

4. Burlingame, Calif.-based Color Genomics: $37 million

5. Atlanta-based Prelude Fertility: $10 million

More articles on data analytics & precision medicine:
Report: 5 states with highest, lowest demand for data science jobs
Indiana U to launch statewide addiction database project
Survey: More than 80% of payers integrate social determinants of health data into programs

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.